Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a quick strike drug stop MS in its tracks?

NCT ID NCT05418010

Disease control Sponsor: Queen Mary University of London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving the drug natalizumab (Tyruko) within two weeks of first MS symptoms can help repair nerve damage. Forty adults with a first episode of MS-like inflammation will receive either the drug or a placebo. The main goal is to see if early treatment improves nerve healing on brain scans after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Natalizumab (Tyruko), a drug that calms the immune system to reduce inflammation in the brain and spinal cord.
What this could lead to
If it works, this could show that starting a strong MS drug very early after first symptoms helps repair nerve damage and leads to better long-term outcomes.
What could go wrong
This is a small, early-phase trial with only 40 people. The drug may not improve nerve repair, and it carries risks like serious brain infections (PML) with long-term use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2022

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Participant has provided informed consent. 2. Age 18-55 years 3. Participant with CIS or MS at first presentation. 4. Participants show two or more lesions on T2 weighted MRI suggestive of demyelination. 5. Participant is willing and able to comply with clinical visits and procedures outlined in the study protocol. Exclusion Criteria: 1. Hypersensitivity to Tyruko® or to any of the following excipients: * Histidine * Histidine monohydrochloride * Sodium chloride * Polysorbate 80 (E433) * Water for injections 2. Evidence of multiple chronic demyelinating lesions on MRI without signs of recent activity. 3. Participants with increased risk for opportunistic infections, including immunocompromised participants (those currently receiving immunosuppressive therapies or those immunocompromised by prior therapies). 4. Combination with other Disease Modifying Treatments.. 5. Known active malignancies, except for participants with cutaneous basal cell carcinoma. 6. Implants such as pacemaker, aneurysm clip in the brain and MRI-incompatible prosthetic heart valves. 7. Significant comorbidities such as cardiac failure, renal failure, uncontrolled diabetes and uncontrolled hypercholesterolemia. 8. History of stroke, thrombosis and/or myocardial infarction. 9. Any other infection deemed, in the assessment of the PI or sub-investigator, clinically significant. 10. Claustrophobia 11. Pregnancy or breastfeeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinically isolated syndrome of demyelination are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease autoimmune disorder of the nervous system Charcot-Marie-Tooth disease type 1F demyelinating disease immune system disorder multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinically isolated syndrome of demyelination Multiple sclerosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Royal London Hospital

    NOT_YET_RECRUITING

    London, E1 1FR, United Kingdom

  • St George's Hospital

    RECRUITING

    London, SW17 0QT, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.